Medline Inc (NASDAQ: MDLN), a leading medical supply company based in Northfield, Illinois, returned to public markets on December 17, 2025. The firm priced its initial public offering (IPO) at $29 per share, raising about $6.26 billion in the largest U.S. IPO this year. Shares jumped 20.7% on their Nasdaq debut, opening at $35.00, reflecting robust investor demand amid continuing interest in healthcare supply chains.

Medline’s IPO Details and Market Reaction

The company issued roughly 216 million Class A common shares in an upsized offering. Underwriters hold a 30-day option to acquire an additional 32.4 million shares, expected to close December 18, subject to standard conditions. Medline plans to apply proceeds from approximately 179 million shares toward repaying its senior secured term loan debt. Remaining funds will cover general corporate expenses and IPO costs, while proceeds from any exercised overallotment shares will be used to redeem equity interests from pre-IPO owners.

The underwriting syndicate was led by Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan. The IPO’s strong debut underscores ongoing investor appetite for durable healthcare sector plays within a challenging macroeconomic backdrop.

Company Overview and Financial Performance

Founded in 1966, Medline is recognized as the largest provider of medical-surgical products and supply chain solutions in North America and beyond. It distributes approximately 335,000 products through two main business segments: Medline Brand and Supply Chain Solutions.

Previously public in the 1970s, Medline went private in 1977. In 2021, the company was acquired from its founding family by private equity firms Blackstone, Carlyle, and Hellman & Friedman in a transaction reported to exceed $30 billion in enterprise value.

Medline operates 69 distribution centers globally, covering over 29 million square feet, supported by a fleet of more than 2,000 trucks. This infrastructure enables next-day delivery to about 95% of U.S. customers. The company employs over 43,000 people and serves customers in more than 100 countries.

For the nine months ended September 27, 2025, Medline reported net sales of $20.6 billion and net income of $1 billion, with an adjusted EBITDA of $2.7 billion. Full-year 2024 results included $25.5 billion in net sales and $1.2 billion in net income, reflecting the company’s significant scale and profitability.

Medline: Market Outlook

Medline’s $6.26 billion IPO and 20.7% share price gain on Nasdaq launch highlight investor confidence in the company’s market position and the healthcare supply industry’s resilience. The capital raised primarily to reduce debt and fund corporate initiatives should support Medline’s ability to maintain and grow its extensive distribution network during a period of heightened global demand for medical products.

With private equity backing and leadership from prominent global underwriters, Medline is well-positioned to capitalize on long-term opportunities in healthcare logistics and supplies. Investors now have a pathway to participate in a business with a proven financial track record and extensive industry footprint, reinforcing its outlook for sustained growth and operational stability.